The IMU Research&Development (R&D) Tax Incentive refund relating to year ending 30.06.23 for $11,741,527 is due to be banked any day now, the next quarterly report for Item 8.4 should include the additional 11,741 as available funding in the total.
Management announced the manufacturing divestment transaction to yield Imugene approximately A$49.0 million (USD$32 million) in cost savings from salaries, drug manufacturing, and overhead costs.(I assume this is for one year) or A$12.25 million per quarter. Therefore future quarterly reports for Item 8.1 should indicate a reduction of 12,250 per quarter. Item 8.5 for the June 2024 quarterly report should indicate IMU has 9 estimated quarters of funding available (until June 2026), i.e. $112,863 divided by $12,962. It would be nice if management would allow shareholders to see a cash flow report for the next 2 years.
Regards.
IMU Price at posting:
8.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)